The FNP Review

The 4 High-Yield Women's Health Topics That Will Show Up on Your FNP Boards

Women's Health · 4 min read · September 21, 2026

Navigating Contraceptive Contraindications Safely

Contraception is a staple on both the AANP and ANCC exams. You are guaranteed to see at least a few questions where a patient wants birth control, but has a complex medical history. The key to answering these correctly is mastering the U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC).

For board purposes, always remember the absolute dealbreakers for Combined Hormonal Contraceptives (CHCs)—which include pills, patches, and vaginal rings. CHCs are contraindicated in women with a history of migraine with aura (due to an increased risk of ischemic stroke), smokers over the age of 35 (due to cardiovascular risks), uncontrolled hypertension, acute deep vein thrombosis (DVT) or pulmonary embolism (PE), and active breast cancer.

Clinical Pearl: If a patient has a history of migraines with aura, never give estrogen. Instead, pivot to progestin-only options like the mini-pill (norethindrone), Depo-Provera injection, the implant, or an IUD.

Decoding Abnormal Uterine Bleeding (AUB)

Abnormal uterine bleeding can feel overwhelming because the differential diagnosis is vast, but the boards love testing your systematic approach. First, remember the acronym PALM-COEIN established by the International Federation of Gynecology and Obstetrics (FIGO). PALM stands for structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy/Hyperplasia), while COEIN stands for non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified).

When a reproductive-aged woman presents with AUB, your very first step—no exceptions—is to rule out pregnancy with a urine or serum hCG. Once pregnancy is excluded, your next evaluation depends heavily on age. For any patient 45 and older, or postmenopausal bleeding at any age, persistent AUB requires an endometrial biopsy to rule out endometrial hyperplasia or carcinoma.

Board Tip: Postmenopausal bleeding is endometrial cancer until proven otherwise. Do not just adjust hormone therapy or wait and see; order an endometrial biopsy or transvaginal ultrasound immediately.

Demystifying Cervical Cancer Screening Guidelines

Cervical cytology guidelines have evolved significantly over the last few years, making it a favorite testing area for board writers who want to catch you using outdated practices. Keep these screening intervals locked in your memory:

  • Ages 21 to 29: Cervical cytology (Pap smear) alone every 3 years. HPV co-testing is not recommended in this age group because transient HPV infections are common and often clear on their own.
  • Ages 30 to 65: You have three acceptable pathways: cytology alone every 3 years, high-risk HPV (hrHPV) testing alone every 5 years, or hrHPV co-testing every 5 years.
  • Under age 21: Screening is not recommended, regardless of the age of sexual initiation.
  • Discontinuation: Screening can stop at age 65 if the patient has had adequate prior negative screening (three consecutive negative cytology results or two consecutive negative co-test results within the past 10 years, with the most recent test performed within the past 5 years).

Clinical Pearl: If a patient has a total hysterectomy for benign reasons and no history of high-grade cervical dysplasia (CIN 2 or higher), routine cytology and HPV screening should be permanently discontinued.

Perimenopause, Menopause, and Hormone Therapy Management

Menopause is diagnosed retrospectively after 12 consecutive months of amenorrhea without another pathological cause, typically occurring around age 51. The hallmark vasomotor symptoms—hot flashes and night sweats—are driven by declining estrogen levels.

When considering Menopausal Hormone Therapy (MHT), the golden rule of thumb for boards is evaluating the presence of a uterus. If a woman has a uterus, she must receive systemic estrogen combined with progesterone (or a progestin) to protect the endometrium from unopposed estrogen stimulation, which drastically increases the risk of endometrial hyperplasia and cancer. Estrogen-only therapy is reserved exclusively for women who have undergone a hysterectomy.

Furthermore, MHT carries risks including venous thromboembolism, stroke, and breast cancer, and is most safely used within 10 years of menopause onset or before age 60 for symptom relief at the lowest effective dose for the shortest duration.

You have everything it takes to master Women's Health and crush your FNP board exam. Keep showing up for yourself every single day, trust your clinical instincts, and let's get you across that pass line! Head over to The FNP Review to access high-yield practice questions and comprehensive study tools designed specifically for future nurse practitioners.